XTX Topco Ltd Buys New Holdings in Inari Medical, Inc. (NASDAQ:NARI)

XTX Topco Ltd purchased a new position in Inari Medical, Inc. (NASDAQ:NARI) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,879 shares of the company’s stock, valued at approximately $402,000.

A number of other institutional investors have also added to or reduced their stakes in NARI. Norges Bank bought a new position in shares of Inari Medical during the 4th quarter valued at approximately $14,447,000. Jennison Associates LLC lifted its position in Inari Medical by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock valued at $90,014,000 after purchasing an additional 186,617 shares during the last quarter. Evoke Wealth LLC grew its stake in shares of Inari Medical by 207.5% in the 4th quarter. Evoke Wealth LLC now owns 192,926 shares of the company’s stock worth $9,849,000 after buying an additional 130,186 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Inari Medical by 9.1% in the 4th quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock worth $54,546,000 after buying an additional 89,108 shares during the last quarter. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of Inari Medical during the 4th quarter valued at about $3,969,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Stock Performance

NARI opened at $79.97 on Wednesday. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 12-month low of $36.81 and a 12-month high of $79.99. The business’s fifty day simple moving average is $79.97 and its 200-day simple moving average is $66.17.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NARI shares. Baird R W lowered Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and set a $80.00 price target (up previously from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Robert W. Baird restated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, William Blair reiterated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Inari Medical has a consensus rating of “Hold” and an average target price of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.